International Journal of Drug Development and Research

Novel Treatment for Drug-Resistance Offers New Hope for Stage IV Breast Cancer Patients

Author info »

References

1. Weiss RB (1992)The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology19: 670-686.
2. Tacar O,Sriamornsak P,DassCR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.The Journal of Pharmacy and Pharmacology65: 157-170.
3. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA (1967)Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer20: 333-353.
4. D R Budman, In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
5. Salzer WL, DevidasM, Carroll WL, Winick N, Pullen J, et al.(2010) Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group. Leukemia24: 355-370.
6. Chaterjee K, Zhang J, Honbo N, Joel SK (2010) Doxorubicin Cardiomyopathy.Cardiology115: 155-162.
7. Edwin R. Manuel, Jeremy Chen, Massimo D'Apuzzo, Melanie G. Lampa, Teodora I. Kaltcheva, et al. (2015) Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res3:444-448.
8. Carol J, Hermansen-Kobulnicky, Joseph B, Wiederholt, Betty Chewning (2004) Adverse Effect Monitoring: Opportunity for Patient Care and Pharmacy Practice. J Am Pharm Assoc44: 75-88.
9. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003)Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549-1563.
10. Rossi S (2013) Australian Medicines Handbook. Adelaide: The Australian Medicines Handbook Unit.